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AM3 (Inmunofero´n) as an adjuvant to hepatitis B vaccination caution techniques in hemodialysis centers, hepatitis B
in hemodialysis patients. vaccination, and the reduction in the need of transfu-
Background. Patients with end-stage renal disease (ESRD) sions, ESRD patients are still at increased risk of hepati-undergoing hemodialysis have severe alterations in cell-medi-
tis B virus (HBV) infection. This contributes significantlyated immunity (CMI) that increases their risk of contracting
to morbidity and mortality [3].chronic hepatitis B virus (HBV) infection and decreases their
protective responses to HBV vaccine. In an effort to improve the Unfortunately, 30 to 40% of hemodialyzed ESRD pa-
humoral response to an accelerated HBV vaccine protocol in tients neither seroconvert nor develop protective anti-
these patients, the ability of an immunomodulator, AM3, to
HBV responses to hepatitis B vaccination [3–10]. Fur-improve seroconversion was investigated.
ther, the duration of any immunity developed is shorterMethods. A total of 269 patients were enrolled in a multicen-
ter trial. All patients received a DNA recombinant vaccine (40 [11, 12], and the secondary immune responses to revacci-
g HBsAg/dose/day) on days 0, 10, 21, and 90. AM3 or placebo nation clearly lower than those observed in healthy peo-
(3 g/day) was given orally for 30 consecutive days beginning ple [13–15]. This suggests that immunological memory15 days prior to the first vaccine dose. Anti-HBsAg titers were
is not firmly established at the time of the first vaccina-measured on days 120 and 270 after the beginning of the trial.
tion. The failure to seroconvert is influenced by age andResults. After one month, 207 patients could be evaluated and
132 patients after six months. The placebo and AM3-treated the degree of renal failure [16]. It also has been associated
groups had comparable seroconversion and protective response with a number of immunological parameters such as dys-
rates one month after the final vaccine dose. The AM3 treat-
functional T-cell responses and decreased in vitro T-cellment group, but not the placebo group, maintained these pro-
proliferation in response to hepatitis B surface antigentective titers up to six months after the final vaccine dose. At
this time, the percentage of high responders (anti-HBsAg100 (HbsAg) [17], altered cytokine production [18–21], and
IU/L) and mean anti-HBsAg titers in the AM3 group was decreased expressions of TCR/CD3, the interleukin-2
significantly higher than in the placebo group. (IL-2) receptor, and human lymphocyte antigen-DRConclusions. AM3 is a safe and easily tolerated oral agent
(HLA-DR) [17].that potentiates long-term serological immunity to hepatitis B
Attempts to increase HBV seroconversion in vacci-in hemodialysis patients after vaccination.
nated, hemodialyzed patients with adjuvant signals such
as cytokine IL-2 [22–25], granulocyte-macrophage col-
In end-stage renal disease (ESRD) patients treated ony-stimulating factor (GM-CSF) [26, 27] and interferon
with hemodialysis, the immune response is impaired and gamma (IFN-) [28] have had no clear effect. Previous
an associated state of chronic inflammation exists [1]. efforts to improve the response to HBV vaccination by
High susceptibility to infections accounts for 36% of the stimulating T-cell and antigen-presenting cell function
mortality of ESRD [2]. Despite the use of universal pre- with immunomodulators (such as thymopentin) have
met with varying degrees of success. The efficacy of thy-
mopentin as an adjuvant to HBV vaccine is controversial.Key words: vaccine, dialysis infection, adjuvant therapy, seroconver-
sion, immunity. Some studies show it to provide either no [29–31] or
only modest [32] benefit.
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latory effects on the production of pro-inflammatory cy- Inclusion criteria. Individuals of both sexes between
the ages of 18 and 80 years with a diagnosis of ESRD,tokines [33–37]. It also increases the absolute number
and activity of natural killer (NK) cells [33–35] and in- who received hemodialysis but who had no detectable
anti-HBsAg titers were eligible for inclusion. These sub-creases both phagocytic cell activity and anti-tumor activ-
ity [35]. In animal models, the capacity of AM3 to po- jects had either never received hepatitis B vaccination or
were repeatedly unable to achieve detectable anti-HBstentiate natural (innate) and specific immunity is related
to the induction of endogenous production of IL-12 and titers after hepatitis B vaccination. Inclusion criteria also
demanded that subjects have undetectable anti-HBs ti-IFN- [36, 37] while partially inhibiting the production
of tumor necrosis factor alpha (TNF-) [37]. AM3’s abil- ters at entry point, and have no serological evidence of
hepatitis B infection [absence of positive serology fority to clinically improve immune activity has been con-
firmed by reductions in respiratory infections in adult hepatitis surface and core antigens (HBsAg, HBeAg),
antibodies to core antigens (anti-HBc), or elevated levelspatients with inflammatory bronchial disease [38] as well
as by the restoration of cutaneous delayed-type hyper- of hepatic transaminases (AST, ALT)]. Further, subjects
had to be able to understand and comply with the studysensitivity reactions in children with asthma [39], reduc-
tions in recurrent aphthous ulcers in oral stomatitis [40], protocol and to sign a note of informed consent.
Exclusion criteria. The following subjects were ex-and in improved viral clearance in chronic hepatitis B
carriers [41, 42]. Further, AM3 has been shown to be an cluded from the study: those unable or unlikely to comply
with the study protocol (for example, drug or alcoholeffective adjuvant in hepatitis B vaccination in healthy
people who previously failed to develop HBsAg titers dependent), pregnant or breast feeding mothers, women
who rejected the use of standard birth control methods,10 IU/mL in response to the recombinant hepatitis B
vaccine [36, 43] as well as in hemodialysis patients who those with previously identified allergies to the hepatitis B
vaccine, Inmunofero´n (AM3) or one of its components,were non-responders to hepatitis B vaccination. The ex-
act mechanism of the immunostimulation effect of AM3 subjects with serology positive for hepatitis B (HBsAg,
HBeAg, anti-HBc), those who showed a humoral responsein these different settings is not well known, although
some studies suggest that a complex process of induction to hepatitis B vaccination greater than 0 IU/L, those
with a congenital or acquired immunodeficiency or auto-of immunoregulatory cytokines is involved [36, 37].
The ability of AM3 to act as an immunoadjuvant in immune disease, those who in the three months prior to
the study had received immunosuppressants, immuno-healthy non-responders to hepatitis B vaccination sug-
gests that it may be helpful in hemodialyzed ESRD pa- modulators, cimetidine or other medications capable of
modifying the immune response, and, finally, those whotients as well. AM3’s stimulatory effects on cell-mediated
and innate immune responses may allow ESRD patients showed evidence of intestinal malabsorption.
Interventions. The study design is outlined in Figure 1.to develop more effective antibody responses to HBV
vaccination. The adjuvant effect of AM3 on the response Hepatitis B vaccine (Recombivax HB, Pasteur Merieux,
MSD Laboratories, Lyon, France) containing 40 g ofto hepatitis B was therefore evaluated in a randomized,
placebo-controlled, double-blind clinical trial of hemodi- HBsAg was administered IM (deltoid) following an ac-
celerated schedule (0, 10, 21, and 90 days). All doses werealyzed ESRD patients.
from the same lot to diminish variation in antigenicity.
Subjects were kept under medical supervision for hyper-
METHODS
sensitivity reactions for half an hour after each adminis-
Protocol tration. Subjects began to take AM3 or placebo 15 days
(d  14) prior to receiving the first 40 g dose ofSubjects. Prior to their inclusion, all recruited subjects
received concise information about the study, were given hepatitis B vaccine (d 0). AM3 (Inmunofero´n; I.F. Can-
tabria, Madrid, Spain) is an oral immunomodulator withthe opportunity to ask questions, and gave their wit-
nessed, informed consent in writing. The study was ap- a low toxicity profile. Previous dose-finding and kinetic
studies with AM3 in pilot studies demonstrated that 3 g/proved by all the ethical committees of the hospitals
involved as well as by their respective national health day is the optimal dose for maximal immunostimulation
without side effects. AM3 or placebo was given by theauthorities. Initial admission studies for inclusion of each
patient involved a brief medical history, a physical exami- oral route at doses of six capsules per day (2 capsules
three times a day) for 30 consecutive days. Whole bloodnation, a complete hemogram, serological studies of hep-
atitis B surface and core antigens and antibodies, serum was drawn into vacutainer tubes for serum collection at
baseline (d 0), 30 days after patients received the finalelectrolyte studies, evaluation of glucose levels, liver
function tests, and the determination of calcium, magne- dose of hepatitis B vaccine (d  120), and six months
after the final vaccine dose (d 270). Anti-HBsAg anti-sium, cholesterol, triglyceride, albumin and uric acid lev-
els. When feasible, serology and hepatitis C RNA detec- body titers, expressed as IU/L, were analyzed by enzyme-
linked immunoassay (ELISA; Ausab, AxSYM; Abbottion also were undertaken.
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Fig. 1. Study outline.
Laboratories, Berkley, CA, USA) with a sensitivity of1 shown in Tables 2 and 3. The treatment groups were
similar across all the measured variables with the excep-IU/L.
Outcome measures. The ability of AM3 to potentiate tion that the AM3 group contained a significantly larger
number of males (and thus showed a mean height sig-the antibody response to hepatitis B vaccine was mea-
sured at one month and six months after the end of the nificantly higher than the placebo group), and that the
placebo group had a significantly greater number of sub-accelerated vaccination protocol. Efficacy was deter-
mined by the percentage of the vaccinated population jects receiving erythropoietin treatment. The 103 patients
who were included in the population used for evaluationin either group achieving seroconversion (10 IU/L) or
who had protective (100 IU/L) anti-HBsAg titers, as of efficacy had similar distributions among baseline char-
acteristics. The significantly higher proportions of maleswell as the concentration of anti-HBsAg titers among
subjects with detectable levels. Our unpublished data in the AM3 group (P  0.01), and of erythropoietin
treated patients in the placebo group (P  0.02), werefrom previous pilot studies indicate that, in response to
hepatitis B vaccination, AM3 treatment increases sero- maintained. The treatment groups did not differ with
respect to nutritional status (weight-for-frame size andconversion from 30% in the placebo group to 60% in
the AM3 treated group in healthy people who did not serum albumin; Table 2), and there were no significant
differences in the dialysis adequacy (Kt/V) betweenrespond to previous vaccination. Thus, for this study,
sample sizes of at least 58 patients per group were needed groups. Importantly, the groups did not differ with re-
spect to mean time spent in dialysis in either the inten-to detect a difference of 30% with a standard deviation
of 10% at 95% power with alpha set at 0.05. It was tion-to-treat population or that used for the evaluation
of efficacy.estimated that 10% of patients would be lost owing to
follow-up or protocol violations. Subjects who had con-
Analysissumed at least 80% of the capsules (placebo or AM3)
were considered in the final evaluation of AM3 efficacy. Safety of AM3 treatment. Adverse events were moni-
tored at each of the vaccine dose administrations (days 0,
Participant flow and follow-up 10,21,90) as well as over the course of the follow-up.
Subjects were instructed to note any adverse events whenSubjects were recruited from 17 European centers.
Two hundred and sixty-nine patients were included in they recorded their daily intake of treatment capsules.
Twenty-five (18.2%) of the AM3 group and 20 (15.1%)the study and randomized to either the placebo (N 
132) or AM3 (N 137) group (Fig. 2). Of the 269 patients of the placebo group reported adverse effects (Table 4).
Mild gastrointestinal symptoms were the only adversewith safety data, 62 withdrew prior to evaluation of effi-
cacy at one month following the final vaccine dose (28 effects likely to be related to the administration of AM3.
Biochemical and hematological parameters measured atplacebo, 34 AM3). An additional 75 subjects withdrew
prior to follow-up six months after the final vaccine dose baseline, immediately after completing AM3 or placebo
treatment, and at the one month follow-up, were not(37 placebo, 38 AM3). Reasons for withdrawal were
equally represented in the AM3 and placebo treatment significantly changed either in the AM3 or placebo group
(data not shown).groups (Table 1). Only four patients from each treatment
group withdrew for adverse effects. Forty-two patients Statistical analysis. All analyses were performed using
SAS for Windows (SAS Inc., Cary, NC, USA). In orderwere excluded from efficacy analysis because of protocol
violations (7 for age 80; 11 for anti-HBsAg titers 0 to ensure accuracy, subject data were entered by two dif-
ferent people into two different databases. The resultingIU/L; 13 for steroid or other immunosuppressive treat-
ments in the 3 months prior to the study or during the databases were compared and merged to form a final
copy. Normality was determined by the Shapiro Wilks testfollow-up; and 11 for non-compliance). The baseline
characteristics of the intention-to-treat population are for sample sizes below 200. Differences between placebo
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Fig. 2. Trial profile.
Table 1. Reasons for withdrawal from study at each end point
One month follow-up Six month follow-up
Placebo AM3 Placebo AM3
Protocol violations
Age 80 years 2 (1.5%) 5 (3.6%) 0 0
Previous anti-HBsAg titers 0 IU/L after primary 6 (4.5%) 5 (3.6%) 0 0
vaccination or previous hepatitis B vaccination or
anti-HBsAg titers 0 IU/L at entrance into study
Treatment with steroids or other immunosuppressors 0 1 (0.7%) 5 (3.7%) 7 (5.1%)
within three months of inclusion in the study or
during the follow-up
Non-compliance with treatment protocol 7 (5.3%) 4 (2.9%) 0 0
Voluntary withdrawal 3 (2.2%) 5 (3.6%) 15 (11.3%) 13 (9.4%)
Death 3 (2.2%) 4 (2.9%) 5 (3.7%) 7 (5.1%)
Renal transplant 3 (2.2%) 6 (4.3%) 2 (1.5%) 1 (0.7%)
Adverse effects 4 (3.0%) 4 (2.9%) 0 0
Transferred to another center 0 0 10 (7.5%) 10 (7.2%)
Total 28 (20.9%) 34 (24.5%) 37 (28.0%) 38 (27.7%)
and treatment groups were compared by the two-tailed pact of patients lost to follow-up or protocol violations,
comparisons were completed on an intention-to-treat basis.Student t test or, when appropriate, by the nonparametric
Mann Whitney U test. Comparisons of categorical vari-
Assignmentables were performed with the aid of the Chi squared
test or, when appropriate, Fisher’s Exact test. Significance Randomization was performed in blocks of four using
a program created using Clipper v. 5.2. One of the twowas set at P 	 0.05 for all analyses. To evaluate the im-
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Table 2. Demographic and baseline information of the intention-to-treat population
Subject characteristics Placebo AM3 P
Gender 0.004
Male 67 (50.8%) 93 (67.9%)
Female 65 (49.2%) 44 (32.1%)
Age in years 132 (60.4
14.7) 137 (60.5
15.0) 0.947
Race —
Caucasian 128 (96.9%) 133 (97.1%)
Other 4 (3.1%) 4 (2.9%)
Height cm 125 (162.5
8.3) 129 (165
8.5) 0.019
Weight kg 131 (64.7
12.1) 134 (66.7
12.9) 0.204
Receiving erythropoietin treatment 113 (85.6%) 103 (75.2%) 0.032
Previously vaccinated against hepatitis B 25 (18.4%) 34 (24.8%) 0.244
Positive for antibodies for hepatitis C (measured in 260) 15 (11.7%) 19 (14.4%) 0.522
Positive for hepatitis C RNA (measured in 64) 8 (26.7%) 9 (26.5%) 1.0
Albumin g/dL 4.0
0.6 3.9
0.4 0.782
Months on hemodialysis 122 (38.4
41.0) 133 (35.3
38.9) 0.540
Data are shown as the N (%) or N (mean 
 SD) as appropriate.
Table 3. Etiology of renal failure in the intention-to-treat population
Placebo AM3 Total
ESRD etiology N (%)
Primary renal 52 (39.4%) 53 (38.7%) 105 (39.0%)
Secondary renal
Diabetes 20 (15.1%) 29 (21.2%) 49 (18.2%)
Vascular/hypertensive disease 22 (16.7%) 25 (18.2%) 47 (17.5%)
Other systemic disease 5 (3.8%) 3 (2.2%) 8 (3.0%)
Interstitial nephritis secondary to analgesics 3 (2.3%) 4 (2.9%) 7 (2.6%)
Chronic renal insufficiency of unknown etiology 30 (22.7%) 23 (16.8%) 53 (19.7%)
Total 132 137 269
Table 4. Adverse events in the intention-to-treat population data were collected, just prior to sending them for off-
site statistical analysis.Placebo AM3
Adverse events N132 N137
MaskingMild gastrointestinal symptoms 6 (4.5%) 4 (2.9%)
Local anaphylactic reaction to vaccination 2 (1.5%) 0 Each patient was given two boxes with 180 capsules
Technical complications of hemodialysis 1 (0.7%) 2 (1.4%)
in individual blister packs as well as a medication diaryArteriovenous graft infection/thrombosis 3 (2.2%) 5 (3.6%)
Anemia 0 1 (0.7%) to record each dose taken. The capsules contained either
Cerebral ischemic accident 0 1 (0.7%) 500 mg of AM3 or placebo (both are flavorless, white
Death 8 (6.0%) 11 (8.0%)
powders). The boxes, the labels on the boxes, and theVertebral fracture and aspiration
capsules for placebo or AM3 were indistinguishable topneumonia 0 1 (0.7%)
both investigator and subject. At the end of the 30-dayTotal 20 (15.1%) 25 (18.2%)
treatment period, subjects handed in their medication
diaries and boxes with blister packs. Investigators and
subjects were therefore blinded to the protocol through-
possible treatments (placebo or AM3) was assigned to out the study period. In an effort to reduce bias, statistical
a list of random numbers. The drug was labeled with a analysis was contracted out to an unrelated party not
number and distributed to each hemodialysis or medical blind to the treatment group.
center in batches of consecutively numbered sets of two
boxes of medicine each. Upon inclusion, each subject was
RESULTSassigned medication in his/her hemodialysis or medical
Serological response to hepatitis B vaccinationcenter corresponding to the lowest number available. For
example, if the center had sets numbered 001 through The adjuvant effect of AM3 on the serological re-
016, the first patient would receive 001, the second would sponse to the accelerated hepatitis B vaccine protocol
receive 002, etc. There were no code violations during was determined by comparing anti-HBsAg titers at one
and six months following the final vaccine dose adminis-the study period. The code was broken after all subject
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Table 5. Serological response to an accelerated protocol of hepatitis B vaccine
One month follow-up Six month follow-up
Placebo AM3 Placebo AM3
N104 N103 N67 N65
Seroconversion (anti-HBsAg 10 IU/L) 65 (62.5%) 72 (69.9%) 42 (62.7%) 42 (64.6%)
Protective response (anti-HBsAg 100 IU/L) 44 (42.3%) 53 (51.5%) 18 (26.9%) 30 (46.2%)a
Low response (10  anti-HBsAg 100 IU/L) 21 (20.2%) 19 (18.4%) 24 (35.8%) 12 (18.4%)
Mean
SD anti-HBsAg titer of those with titers 0 IU/L 624.9
1149.6 675.7
1389.0 199.7
285.9 330.4
340.2b
a Significantly more subjects from AM3 group than placebo group developed protective responses, P  0.03
b Mean anti-HBsAg titers are significantly greater in AM3 group as compared to placebo, P  0.02
tered (Table 5). Both treatment groups had rates of study. There were no significant differences in these vac-
seroconversion greater than 60% at one and six months cination response parameters between such patients in
after the final vaccine dose. No significant differences were both treated groups after the first month of study (data
seen in the rates of seroconversion between treatment not shown). These findings, combined with the parallel
groups. Further, at the one month follow-up, 53 out of loss of subjects in both treatment groups, argue against
103 patients on AM3, and 44 out of 104 patients on any bias being introduced by subject withdrawal.
placebo, developed protective titers (anti-HBsAg 100
IU/L). While seroconversion rates were relatively well
DISCUSSIONmaintained up to six months after the final vaccine dose,
This randomized, placebo-controlled clinical trial dem-the percentage of subjects with protective titers fell sig-
onstrates a clear role for AM3 as an adjuvant to hepatitisnificantly in the placebo group. While the AM3 group
B vaccination in hemodialyzed ESRD patients for thehad 46.2% (30 of 65) subjects with protective titers, the
development of prolonged anti-HBsAg protective titers.placebo group at the final follow-up included only 26.9%
The clinical relevance of achieving anti-HBsAg titers(18 of 67) subjects with protective titers (P  0.03). In
100 IU/L after vaccination has been well established inaddition, while both groups demonstrated declines in
immunocompromised patients [7, 12, 44, 45] as well as inmean titers from the one month to the six month fol-
infants at high risk of hepatitis B infection [46]. Further,low-up, the AM3 group had significantly higher mean
some authors [51], as well as some countries (United King-titers than did the placebo group at six months after the
dom) [45–48], have recommended adopting 100 IU/L asfinal vaccine dose. At one and six months after the final
the minimum protective titer against a hazardous hepa-vaccine dose, there were no significant differences be-
titis B infection in healthy people.tween groups of patients with respect to low titers of
Hemodialyzed ESRD patients achieve lower antibodyanti-HBsAg antibodies (10  anti-HBsAg 100 IU/L).
titers after vaccination, lose antibody titers more rapidly,In the group of 100 naı¨ve vaccinated patients, those
and have a higher risk of natural infection after vacci-treated with AM3 showed a significantly better response
nation than do healthy subjects [4, 8, 12]. Since increasedto the hepatitis B vaccination (26 developed protective
cell-mediated immune (CMI) responses against hepa-response, 7 low titers and 13 did not seroconvert) than
titis B are associated with higher humoral responses tothose treated with the placebo (15 developed protective
vaccination [49–51], it is reasonable that an adjuvantresponse, 21 low titers and 18 did not seroconvert; P 
that supports CMI function such as AM3 [35–37] would0.006). There were no significant differences between
improve long-term serological immunity following vac-the AM3 and placebo treatments with respect to the
cination.rates and levels of seroconversion in the 32 patients who
Two factors varied unequally between the placebo andhad failed in former vaccination protocols.
AM3 groups. The latter showed a significantly greaterThe number of patients lost to follow-up in the popula-
percentage of males than did the placebo group. Previoustion used for evaluation of efficacy was similar in the
studies have demonstrated that hemodialyzed femalestwo patient groups (Fig. 2). Comparative analysis of the
[9], as well as healthy adult women [49, 52], have signifi-rates of seroconversion, protective titers and mean anti-
cantly better serological responses to vaccination than doHBsAg titers of those patients who did not reach the
men. The greater percentage of men in the AM3 groupsix-month endpoint (N  75) showed no significant dif-
(Table 2) could therefore have introduced a bias againstferences between the AM3 and placebo groups at one
the efficacy of AM3. Secondly, although the use of eryth-month following vaccination (data not shown). Further,
ropoietin was high in both treatment groups, the placebowe analyzed the rates of seroconversion, protective titers
group had a significantly greater number of subjects re-and mean anti-HBsAg titers of the patients lost after
the first month of follow-up and those remaining in the ceiving this medication than did the AM3 group (Table 2).
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